Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy

Li,Changyou; Xu,Jing; Wang,Qi; Geng,Shaoqing; Yan,Zheng; You,Jin; Li,Zhenfeng; Zou,Xiao

doi:10.3892/ol.2018.8310

Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy

Authors:
- Changyou Li
- Jing Xu
- Qi Wang
- Shaoqing Geng
- Zheng Yan
- Jin You
- Zhenfeng Li
- Xiao Zou
View Affiliations

Affiliations: Biotherapy Center, Qingdao Central Hospital, The Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, P.R. China, Department of Pathology, Qingdao Central Hospital, The Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, P.R. China, Department of Pathology, Qingdao Cancer Hospital, The Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, P.R. China, Department of Breast Surgery, Qingdao Central Hospital, The Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, P.R. China, Anorectal Department, Qingdao Central Hospital, The Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, P.R. China
Published online on: March 21, 2018 https://doi.org/10.3892/ol.2018.8310
Pages: 8072-8078

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was performed to explore the prognostic significance of periostin expression in a cohort of patients with early‑stage breast cancer treated with breast conserving surgery following radiotherapy. A tissue microarray of tumor samples from 259 patients with early‑stage breast cancer was assayed for periostin, estrogen receptor (ER), progesterone receptor (PR), ErbB2 receptor tyrosine kinase 2 and Ki‑67 expression by immunohistochemistry. The association of periostin with other clinicopathological parameters and clinical outcomes, including local recurrence free survival (RFS), distant metastasis free survival (DFS) and overall survival (OS), were assessed through log‑rank tests and univariate and multivariate analysis. Periostin expression was identified in 91 of the 259 tissue samples (35%). The periostin status was significantly associated with histological grade (P=0.001), nodal status (P=0.023), molecular subtype (P<0.01), ER status (P<0.01), PR status (P<0.01) and Ki‑67 expression (P=0.011). Furthermore, periostin expression was associated with an increased risk of five‑year local recurrence (95.8% vs. 89.0%; P=0.017) and distant metastasis (92.3% vs. 79.1%; P=0.001) in patients with early stage breast cancer. Multivariate analysis using Cox's proportional hazards model demonstrated that periostin expression was an independent predictor of all clinical outcomes in breast cancer (RFS, P=0.018; DFS, P=0.025; OS, P=0.047). Therefore, it was concluded that periostin is associated with an increased risk of local relapse and distant metastasis in early‑stage breast cancer treated with conserving surgery and radiotherapy. This association should be further investigated in larger cohorts to validate the clinical significance of periostin expression.

View Figures

View References

1	Gaffan J, Dacre J and Jones A: Educating undergraduate medical students about oncology: A literature review. J Clin Oncol. 24:1932–1939. 2006. View Article : Google Scholar : PubMed/NCBI
2	Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R and Fourquet A: Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol. 82:272–280. 2007. View Article : Google Scholar : PubMed/NCBI
3	Hanahan D and Coussens LM: Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
4	Wang Z and Ouyang G: Periostin: A bridge between cancer stem cells and their metastatic niche. Cell Stem Cell. 10:111–112. 2012. View Article : Google Scholar : PubMed/NCBI
5	Zhang Y, Zhang G, Li J, Tao Q and Tang W: The expression analysis of periostin in human breast cancer. J Surg Res. 160:102–106. 2010. View Article : Google Scholar : PubMed/NCBI
6	Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF and Huelsken J: Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 481:85–89. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kyutoku M, Taniyama Y, Katsuragi N, Shimizu H, Kunugiza Y, Iekushi K, Koibuchi N, Sanada F, Oshita Y and Morishita R: Role of periostin in cancer progression and metastasis: Inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med. 28:181–186. 2011.PubMed/NCBI
8	Xiao ZM, Wang XY and Wang AM: Periostin induces chemoresistance in colon cancer cells through activation of the pi3k/akt/survivin pathway. Biotechnol Appl Biochem. 62:401–406. 2015. View Article : Google Scholar : PubMed/NCBI
9	Sung PL, Jan YH, Lin SC, Huang CC, Lin H, Wen KC, Chao KC, Lai CR, Wang PH, Chuang CM, et al: Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Oncotarget. 7:4036–4047. 2016. View Article : Google Scholar : PubMed/NCBI
10	Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H and Lu P: Cancer stem cell-related gene periostin: A novel prognostic marker for breast cancer. PLoS One. 7:e466702012. View Article : Google Scholar : PubMed/NCBI
11	Nuzzo PV, Rubagotti A, Argellati F, Di Meglio A, Zanardi E, Zinoli L, Comite P, Mussap M and Boccardo F: Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa). Int J Mol Sci. 16:17181–17192. 2015. View Article : Google Scholar : PubMed/NCBI
12	American Joint Committee on Cancer: Cancer Staging Handbook: From the AJCC Cancer Staging Manual. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene F and Trotti A: 7th edition. Springer-Verlag; New York: pp. 3472010
13	Lakhani SR, Ellis IO, Schnitee SJ, Tan PH and van de Vijver MJ: WHO Classification of Tumours of the Breast. 4. 4th. IARC Press; Lyon: 2012
14	Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Rody A, Schaefer KL, Baldus SE, Hartmann A, et al: Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res. 13:488–497. 2007. View Article : Google Scholar : PubMed/NCBI
15	Gebski V, Lagleva M, Keech A, Simes J and Langlands AO: Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective. J Natl Cancer Inst. 98:26–38. 2006. View Article : Google Scholar : PubMed/NCBI
16	Rosen JM and Jordan CT: The increasing complexity of the cancer stem cell paradigm. Science. 324:1670–1673. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lagadec C, Vlashi E, Della Donna L, Dekmezian C and Pajonk F: Radiation-induced reprogramming of breast cancer cells. Stem Cells. 30:833–844. 2012. View Article : Google Scholar : PubMed/NCBI
18	Phillips TM, McBride WH and Pajonk F: The response of cd24^−/low/cd44⁺ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
19	Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, et al: HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res. 18:6634–6647. 2012. View Article : Google Scholar : PubMed/NCBI
20	Rycaj K and Tang DG: Cancer stem cells and radioresistance. Int J Radiat Biol. 90:615–621. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lambert AW, Wong CK, Ozturk S, Papageorgis P, Raghunathan R, Alekseyev Y, Gower AC, Reinhard BM, Abdolmaleky HM and Thiagalingam S: Tumor cell-derived periostin regulates cytokines that maintain breast cancer stem cells. Mol Cancer Res. 14:103–113. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F and Yuan YZ: Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol. 34:821–828. 2009.PubMed/NCBI
23	Hong L, Sun H, Lv X, Yang D, Zhang J and Shi Y: Expression of periostin in the serum of nsclc and its function on proliferation and migration of human lung adenocarcinoma cell line (a549) in vitro. Mol Biol Rep. 37:2285–2293. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lv Y, Wang W, Jia WD, Sun QK, Huang M, Zhou HC, Xia HH, Liu WB, Chen H, Sun SN and Xu GL: High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Eur J Surg Oncol. 39:1129–1135. 2013. View Article : Google Scholar : PubMed/NCBI
25	Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB and Elias A: Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 77:245–252. 2003. View Article : Google Scholar : PubMed/NCBI